Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 12.37%5.18B | ---- | -23.61%4.61B | ---- | -44.03%6.04B | ---- | -23.44%10.79B | ---- | 10.73%14.09B |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | 43.67%-214.79M | ---- | -26.56%-381.33M | ---- | -6.62%-301.29M | ---- | -85.21%-282.6M | ---- | -0.49%-152.58M |
| Investment loss (gain) | ---- | ---- | ---- | ---- | ---- | ---254.02M | ---- | ---- | ---- | ---- |
| Attributable subsidiary (profit) loss | ---- | 36.56%-441.3M | ---- | -185.27%-695.64M | ---- | 83.01%-243.86M | ---- | 10.74%-1.44B | ---- | -64.76%-1.61B |
| Impairment and provisions: | ---- | -17.15%568.03M | ---- | 2,236.88%685.6M | ---- | -106.45%-32.08M | ---- | 81.25%497.08M | ---- | 69.63%274.25M |
| -Impairment of trade receivables (reversal) | ---- | -17.15%568.03M | ---- | 2,236.88%685.6M | ---- | ---32.08M | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 81.25%497.08M | ---- | 177.57%274.25M |
| Revaluation surplus: | ---- | -90.85%15.69M | ---- | 228.29%171.59M | ---- | -157.57%-133.75M | ---- | 171.52%232.31M | ---- | -1,918.37%-324.83M |
| -Fair value of investment properties (increase) | ---- | -56.31%41.34M | ---- | 170.71%94.64M | ---- | 61.72%-133.85M | ---- | -792.00%-349.68M | ---- | -329.43%-39.2M |
| -Derivative financial instruments fair value (increase) | ---- | ---17.63M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other fair value changes | ---- | -110.42%-8.02M | ---- | 75,342.16%76.95M | ---- | -99.98%102K | ---- | 303.76%581.99M | ---- | -36,860.88%-285.63M |
| Asset sale loss (gain): | ---- | -162.67%-510.57M | ---- | -2,526.06%-194.38M | ---- | 103.11%8.01M | ---- | -485.23%-257.79M | ---- | 1,598.43%66.92M |
| -Loss (gain) from sale of subsidiary company | ---- | -197.30%-515.97M | ---- | -3,331.82%-173.55M | ---- | 101.98%5.37M | ---- | -666.42%-271.21M | ---- | 661.65%47.88M |
| -Loss (gain) on sale of property, machinery and equipment | ---- | 108.51%1.77M | ---- | -256.82%-20.83M | ---- | -1.03%13.28M | ---- | -16.72%13.42M | ---- | 29.27%16.11M |
| -Loss (gain) from selling other assets | ---- | --3.62M | ---- | ---- | ---- | ---10.64M | ---- | ---- | ---- | --2.92M |
| Depreciation and amortization: | ---- | 3.61%3.02B | ---- | 3.50%2.91B | ---- | 8.47%2.81B | ---- | 21.20%2.59B | ---- | 21.24%2.14B |
| -Amortization of intangible assets | ---- | -1.59%178.53M | ---- | -4.23%181.41M | ---- | 7.11%189.41M | ---- | 6.34%176.84M | ---- | 24.09%166.29M |
| Financial expense | ---- | -15.06%1.8B | ---- | 14.36%2.12B | ---- | 27.38%1.86B | ---- | 2.66%1.46B | ---- | --1.42B |
| Exchange Loss (gain) | ---- | 56.28%-34.3M | ---- | -276.14%-78.44M | ---- | 67.27%-20.86M | ---- | 21.15%-63.73M | ---- | -248.41%-80.82M |
| Special items | ---- | -98.14%2.92M | ---- | 231.22%156.8M | ---- | --47.34M | ---- | ---- | ---- | 99.87%-122K |
| Operating profit before the change of operating capital | ---- | 0.83%9.39B | ---- | -4.77%9.31B | ---- | -27.73%9.78B | ---- | -14.51%13.53B | ---- | 6.27%15.82B |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -46.99%398.23M | ---- | 233.51%751.31M | ---- | -208.10%-562.75M | ---- | 89.20%-182.65M | ---- | -1,807.49%-1.69B |
| Accounts receivable (increase)decrease | ---- | -64.51%742.43M | ---- | 313.58%2.09B | ---- | 69.26%-979.53M | ---- | -107.43%-3.19B | ---- | -170.65%-1.54B |
| Accounts payable increase (decrease) | ---- | 73.57%-293.85M | ---- | -514.23%-1.11B | ---- | -136.59%-181.04M | ---- | -16.36%494.78M | ---- | 116.55%591.57M |
| Derivative financial instruments (increase) decrease | ---- | --11.75M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Special items for working capital changes | ---- | -250.92%-2.49B | ---- | -53.96%1.65B | ---- | 200.35%3.59B | ---- | 158.56%1.2B | ---- | 58.50%-2.04B |
| Cash from business operations | ---- | -38.94%7.75B | ---- | 9.04%12.69B | ---- | -1.74%11.64B | ---- | 6.28%11.85B | ---- | 28.57%11.15B |
| China income tax paid | ---- | 3.18%-1.31B | ---- | 16.18%-1.35B | ---- | 18.11%-1.61B | ---- | 31.28%-1.97B | ---- | -31.33%-2.87B |
| Special items of business | -15.09%3.13B | ---- | -51.31%3.68B | ---- | 59.74%7.57B | ---- | 14.30%4.74B | ---- | -39.85%4.14B | ---- |
| Net cash from operations | -15.09%3.13B | -43.20%6.44B | -51.31%3.68B | 13.09%11.34B | 59.74%7.57B | 1.53%10.03B | 14.30%4.74B | 19.30%9.88B | -39.85%4.14B | 27.64%8.28B |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | -43.67%214.79M | ---- | 26.56%381.33M | ---- | 6.62%301.29M | ---- | 85.21%282.6M | ---- | 0.49%152.58M |
| Dividend received - investment | ---- | 62.87%619.42M | ---- | -7.06%380.32M | ---- | 42.21%409.2M | ---- | -6.19%287.74M | ---- | 78.32%306.73M |
| Loan receivable (increase) decrease | ---- | 192.31%1.67B | ---- | -18.64%-1.81B | ---- | -122.16%-1.52B | ---- | -15,246.89%-685.7M | ---- | 98.54%-4.47M |
| Decrease in deposits (increase) | ---- | -675.33%-126.45M | ---- | -16.93%-16.31M | ---- | -112.81%-13.95M | ---- | -64.49%108.88M | ---- | 199.60%306.58M |
| Sale of fixed assets | ---- | -20.57%190.64M | ---- | 63.68%240.01M | ---- | 4.90%146.64M | ---- | 167.10%139.79M | ---- | -25.04%52.34M |
| Purchase of fixed assets | ---- | 22.72%-4.64B | ---- | -2.09%-6B | ---- | 33.28%-5.88B | ---- | -8.42%-8.81B | ---- | -16.17%-8.13B |
| Selling intangible assets | ---- | -7.35%33.8M | ---- | --36.48M | ---- | ---- | ---- | 33.63%14.97M | ---- | 3,109.17%11.2M |
| Purchase of intangible assets | ---- | 38.81%-37.1M | ---- | 25.75%-60.63M | ---- | 58.84%-81.66M | ---- | 11.33%-198.42M | ---- | -70.25%-223.77M |
| Sale of subsidiaries | ---- | -21.41%570.84M | ---- | 3,109.85%726.33M | ---- | -90.17%22.63M | ---- | 812.96%230.11M | ---- | 181.71%25.21M |
| Acquisition of subsidiaries | ---- | -193.29%-6.19M | ---- | 568.88%6.63M | ---- | 99.32%-1.41M | ---- | 67.87%-207.96M | ---- | -11.10%-647.17M |
| Recovery of cash from investments | ---- | 361.43%30.23M | ---- | -95.86%6.55M | ---- | 555.56%158.16M | ---- | -59.86%24.13M | ---- | --60.11M |
| Cash on investment | ---- | 82.66%-158.69M | ---- | 12.51%-915.35M | ---- | 65.61%-1.05B | ---- | -1,179.40%-3.04B | ---- | 82.65%-237.79M |
| Other items in the investment business | 64.25%-522.37M | -403.81%-141.97M | 43.61%-1.46B | ---28.18M | 33.48%-2.59B | ---- | 46.20%-3.9B | ---348.32M | -133.81%-7.24B | ---- |
| Net cash from investment operations | 64.25%-522.37M | 74.76%-1.78B | 43.61%-1.46B | 6.07%-7.05B | 33.48%-2.59B | 38.49%-7.51B | 46.20%-3.9B | -46.62%-12.21B | -133.81%-7.24B | 11.95%-8.32B |
| Net cash before financing | 17.23%2.6B | 8.68%4.66B | -55.33%2.22B | 70.19%4.29B | 491.59%4.97B | 208.21%2.52B | 127.16%840.83M | -4,971.33%-2.33B | -181.64%-3.1B | 98.45%-45.92M |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | 14.25%36.51B | ---- | -13.75%31.95B | ---- | -7.69%37.05B | ---- | 13.07%40.13B | ---- | 28.11%35.49B |
| Refund | ---- | -8.94%-34.38B | ---- | -4.44%-31.56B | ---- | 13.33%-30.22B | ---- | -17.52%-34.87B | ---- | -22.50%-29.67B |
| Issuing shares | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --11.6B | ---- | ---- |
| Interest paid - financing | ---- | 17.49%-2.27B | ---- | -11.08%-2.75B | ---- | -17.36%-2.48B | ---- | -10.85%-2.11B | ---- | -3.42%-1.9B |
| Dividends paid - financing | ---- | -3.71%-3.41B | ---- | 9.77%-3.29B | ---- | 6.78%-3.65B | ---- | -34.93%-3.91B | ---- | -10.49%-2.9B |
| Absorb investment income | ---- | -68.40%23.24M | ---- | -54.79%73.55M | ---- | -53.39%162.7M | ---- | 28.78%349.03M | ---- | 182.34%271.04M |
| Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | ---43.91M | ---- | ---- | ---- | -2,042.29%-2.85B | ---- | ---132.9M |
| Other items of the financing business | 160.74%1.04B | -442.31%-200.96M | 51.79%-1.71B | 98.21%-37.06M | -188.55%-3.54B | 53.31%-2.07B | -35.26%4B | -4,043.84%-4.43B | 318.65%6.18B | 93.69%-106.9M |
| Net cash from financing operations | 160.74%1.04B | 35.08%-3.81B | 51.79%-1.71B | -314.78%-5.86B | -188.55%-3.54B | -138.27%-1.41B | -35.26%4B | 326.84%3.69B | 318.65%6.18B | 132.52%865.58M |
| Effect of rate | -63.44%211.86M | 87.66%-94.9M | 165.14%579.51M | -13.50%-769.18M | 14.68%-889.61M | -293.17%-677.71M | -1,328.06%-1.04B | -1.13%350.83M | -75.57%84.91M | 172.48%354.85M |
| Net Cash | 607.31%3.64B | 154.20%853.91M | -64.07%514.9M | -242.42%-1.58B | -70.39%1.43B | -19.02%1.11B | 57.08%4.84B | 66.65%1.37B | 218.60%3.08B | 114.56%819.66M |
| Begining period cash | 9.38%8.85B | -22.46%8.09B | -22.46%8.09B | 4.28%10.44B | 4.28%10.44B | 20.70%10.01B | 20.70%10.01B | 16.50%8.29B | 16.50%8.29B | -46.23%7.12B |
| Cash at the end | 38.29%12.71B | 9.38%8.85B | -16.33%9.19B | -22.46%8.09B | -20.46%10.98B | 4.28%10.44B | 20.49%13.81B | 20.70%10.01B | 35.88%11.46B | 16.50%8.29B |
| Cash balance analysis | ||||||||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Deloitte Touche Tohmatsu CPA LLP | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.